TITLE

NeuroAIDS in sub Saharan Africa: A clinical review

AUTHOR(S)
Alkali, Nura H.; Bwala, Sunday A.; Nyandaiti, Yakubu W.; Danesi, Mustapha A.
PUB. DATE
March 2013
SOURCE
Annals of African Medicine;2013, Vol. 12 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
NeuroAIDS affects half of the 22 million people currently living with HIV/AIDS in sub Saharan Africa, where cryptococcal meningitis alone is responsible for 504,000 deaths annually. A good understanding of NeuroAIDS may help improve disease free survival in patients at risk and optimize resource utilization by caregivers. In this review, we aimed to provide a summary of major NeuroAIDS syndromes of relevance in Africa. We searched Medline for English language literature to identify relevant publications, using the search terms "NeuroAIDS" and "HIV AND nervous system." The most common NeuroAIDS syndrome is HIV associated neurocognitive disorders (HAND), which affects over 1.5 million Africans yearly. While incidence of HAND has decreased with the use of highly active antiretroviral therapy, prevalence has increased due to longer life expectancy. Other NeuroAIDS syndromes include tuberculous meningitis and intracerebral tuberculoma, cryptococcal meningitis, toxoplasma encephalitis, progressive multifocal leukoencephalopathy, primary central nervous system lymphoma, stroke, and distal sensory polyneuropathy. NeuroAIDS care and research in Africa are hindered by resource limitations. Inadequate neuroimaging and laboratory facilities result in diagnostic delays and confusion, while limited access to drugs leads to inappropriate treatment. However, the situation may be improving. Better funding of HIV care by African governments and donor agencies have resulted in decreasing HIV prevalence and prolonged survival. Yet, central nervous system opportunistic infections remain important causes of death and disability among African patients with HIV/AIDS. There is the need for additional funding to improve access to antibiotics and to facilitate further research into NeuroAIDS and its treatment.
ACCESSION #
86867642

 

Related Articles

  • Reconsidering Cryptococcal Antigen Screening in the U.S. Among Persons With CD4 <100 cells/mcL. Rajasingham, Radha; Boulware, David R. // Clinical Infectious Diseases;Dec2012, Vol. 55 Issue 12, p1742 

    The article focuses on the prevention strategies which can be employed for resisting the change of HIV cases in AIDS. It informs that Cryptococcal meningitis is an opportunistic infection that causes 20 percent 25 percent AIDS related mortality in Africa. It also discusses the use of...

  • Preface [Hot Topic: Anti-HIV Drugs and Therapy (Executive Editor : Ted M. Ross)]. Ros, Ted M. // Current Pharmaceutical Design;Jul2003, Vol. 9 Issue 18, p1 

    Since the first cases of an unknown cancer were identified in gay men in the United States in the early 1980's, approximately 100 million individuals worldwide have been infected with the human immunodeficiency virus (HIV) and developed the disease known as acquired immunodeficiency syndrome...

  • HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. Andrew Lucas; David Nolan; Simon Mallal // Journal of Antimicrobial Chemotherapy (JAC);Mar2007, Vol. 59 Issue 4, p591 

    The introduction of highly active antiretroviral therapy (also known as combination therapy) has transformed the nature of HIV infection from a severe and ultimately fatal disease to that of a manageable chronic condition. HIV drugs are highly efficacious, but their use comes at the cost of a...

  • AIDSLINE. Waites, Larry // Advocate;6/16/92, Issue 605, p76 

    Presents a question-and-answer advisory concerning AIDS in the U.S. Tips on how and when to choose an antiviral for HIV-positive patients; Effectiveness of combination antiviral therapy; Commentary on Luc Montaigner's claims that HIV does not cause AIDS.

  • Antiviral briefs.  // AIDS Patient Care & STDs;Mar1998, Vol. 12 Issue 3, p229 

    Presents news briefs in relation to acquired immunodeficiency syndrome (AIDS) and human immunodeficiency virus (HIV) patients care and sexually transmitted diseases (STDs). Findings on the use of ranitidine for HIV infection; Views of doctor Paul A. Volberding of the University of California at...

  • Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. Lifson, Alan R.; Krantz, Elizabeth M.; Eberly, Lynn E.; Dolan, Matthew J.; Marconi, Vincent C.; Weintrob, Amy C.; Crum-Cianflone, Nancy F.; Ganesan, Anuradha; Grambsch, Patricia L.; Agan, Brian K. // AIDS Research & Therapy;2011, Vol. 8, p1 

    Background: Among HIV-infected persons initiating highly active antiretroviral therapy (HAART), early CD4+ lymphocyte count increases are well described. However, whether CD4+ levels continue to increase or plateau after 4-6 years is controversial. Methods: To address this question and identify...

  • The Search for Data on When to Start Treatment for HIV Infection. Hughes, Michael D.; Ribaudo, Heather R. // Journal of Infectious Diseases;4/15/2008, Vol. 197 Issue 8, p1034 

    The author presents the data gathered by the Strategies for Management of Antiretroviral Therapy (SMART) which are relevant to the potential application of antiretroviral therapy (ART) for infection with HIV. The study reveals that HIV-infected subjects who immediately initiated ART have...

  • HIV/AIDS: Recent Advances in Antiretroviral Agents. Nikolopoulos, Georgios; Bonovas, Stefanos; Tsantes, Argirios; Sitaras, Nikolaos M. // Mini Reviews in Medicinal Chemistry;Jul2009, Vol. 9 Issue 8, p900 

    Despite the considerable progress in antiretroviral therapy, the eradication of HIV-1 remains unfeasible. Therefore, novel agents are under investigation. The aim of this review is to summarize the conventional compounds, to describe the recently approved agents, and to take a comprehensive look...

  • Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 ‘non-B’-infected patients. Charpentier, Charlotte; Larrouy, Lucile; Visseaux, Benoit; Landman, Roland; Levittas, Marine; Storto, Alexandre; Damond, Florence; Yazdanpanah, Yazdan; Yeni, Patrick; Brun-Vézinet, Françoise; Descamps, Diane // Journal of Antimicrobial Chemotherapy (JAC);Jun2012, Vol. 67 Issue 6, p1459 

    Objectives BMS-626529 is a member of the new drug class of HIV-1 attachment inhibitors currently in development. Mutations selected during in vitro experiments with BMS-626529 are located in the gp120 region: L116P, A204D, M426L, M434I-V506M and M475I. A differential antiviral activity of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics